University of Hertfordshire

  • Paul Kamudoni
  • Dagmar Amtmann
  • Jeffrey Johns
  • Karon F. Cook
  • Rana Salem
  • Sam Salek
  • Jana Raab
  • Rod Middleton
  • Pavle Repovic
  • Kevin N. Alschuler
  • Gloria von Geldern
  • Annette Wundes
  • Amy Barrett
  • Oyebimpe Olayinka-Amao
  • Christian Henke
View graph of relations
Original languageEnglish
Article number103753
Number of pages12
JournalMultiple Sclerosis and Related Disorders
Volume62
Early online date21 Mar 2022
DOIs
Publication statusPublished - 1 Jun 2022

Abstract

Background
A valid, sensitive patient-reported outcome (PRO) measure of physical function (PF) for people with multiple sclerosis (MS) would have substantial value in routine care and clinical research. We now describe development of the PROMISnq Short Form v2.0 PF – Multiple Sclerosis 15a [PROMISnq PF(MS)15a] for assessing PF in relapsing and progressive MS. Also, the validity, reliability, and responsiveness of the PROMISnq PF(MS)15a is evaluated, minimal important difference (MID) thresholds for score change estimated and a score interpretation guide developed.

Methods
A mixed-methods sequential design was employed. Relevant PF concepts were elicited through semi-structured interviews with people with relapsing MS, and then mapped to the PROMIS PF item bank. Measurement experts integrated results from interviews with people with MS and input from a panel of neurologists to generate a draft short form. Relevance and comprehensiveness of the draft short form were assessed in cognitive debriefing interviews with people with relapsing or progressive MS. Subsequently, item reduction and evaluation of psychometric properties were performed in two observational studies: a cross-sectional study in the US (n = 296), and a 96-week longitudinal study in the UK MS Register cohort (n = 558). The main outcomes and measures are estimates of: known-groups validity, convergent validity, reliability, responsiveness; MID for worsening.

Results
Factor analyses supported the unidimensionality of the newly derived 15-item short form. Cronbach's alpha (≥ 0.97) and intraclass correlation coefficient (≥ 0.97) of test-retest scores (5–27 days) indicated strong reliability. Convergent validity was demonstrated by moderate-to-strong correlations with scores on related PRO measures. Scores discriminated among patient groups classified by levels of physical health and other criteria. Score changes of 2.3–2.7 points are proposed as MID criteria for minimal worsening in PF.

Conclusion
PROMISnq PF(MS)15a demonstrated reliability, validity and sensitivity to change. Input from patients and clinicians ensured the content is comprehensive and relevant for people with MS.

Notes

© 2022 Published by Elsevier B.V.

ID: 27388360